BioN­Tech rais­es mam­moth $270M A round, near­ing $1B mark as in­vestors con­tin­ue a love af­fair with mR­NA

Of all the star­tups on both con­ti­nents over the past decade, few could ri­val the growth of BioN­Tech af­ter it got start­ed with seed cash back in 2008. The mR­NA com­pa­ny has fund­ed much of its rapid ex­pan­sion with part­ner­ship cash, reach­ing more than 700 staffers at the end of 2017 with the con­sid­er­able sup­port of some big al­liances with the likes of Genen­tech and Sanofi and Gen­mab.

Un­til to­day.

This morn­ing the Mainz, Ger­man-based biotech took the wraps off a mega-raise of $270 mil­lion — an ‘A’ round de­signed to com­plete the rapid ramp-up of its con­sid­er­able man­u­fac­tur­ing op­er­a­tions as it looks to ad­vance an ear­ly-stage per­son­al­ized mR­NA can­cer vac­cine de­signed to mob the anti­gens of in­di­vid­ual pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER